Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susana Clemente

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 27, 2026
[Translated article] Positioning of the Spanish Society of Hospital Pharmacists in solid organ transplantationAna María Sangrador Rasero, Mar Gomis Pastor, Sara Ibañez García, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 12, 2026
Positioning of the Spanish Society of Hospital Pharmacists in solid organ transplantationAna María Sangrador Rasero, Mar Gomis Pastor, Sara Ibañez García, et al.
Pharmaceutics|January 8, 2025
Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World StudySusana Clemente Bautista, Óscar Segarra Cantón, Núria Padullés-Zamora, et al.
Paediatric Drugs|March 20, 2024
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic ModelSusana Clemente-Bautista, Iñaki F Trocóniz, Óscar Segarra-Cantón, et al.
ERJ Open Research|January 27, 2022
Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countriesOle Hilberg, Anna-Maria Hoffmann-Vold, Vanessa Smith, et al.
Pharmacological Research|July 20, 2023
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in childrenPaula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 24, 2024
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatmentSara Salvador-Martín, Gianluca Rubbini, Perceval Vellosillo, et al.
International Journal of Molecular Sciences|January 21, 2023
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease CohortSara Salvador-Martín, Paula Zapata-Cobo, Marta Velasco, et al.
Pharmaceutics|January 12, 2021
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel DiseaseSara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, et al.
British Journal of Clinical Pharmacology|June 2, 2020
Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel diseaseSara Salvador-Martín, Gemma Pujol-Muncunill, Ferran Bossacoma, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 27, 2026
[Translated article] Positioning of the Spanish Society of Hospital Pharmacists in solid organ transplantationAna María Sangrador Rasero, Mar Gomis Pastor, Sara Ibañez García, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 12, 2026
Positioning of the Spanish Society of Hospital Pharmacists in solid organ transplantationAna María Sangrador Rasero, Mar Gomis Pastor, Sara Ibañez García, et al.
Pharmaceutics|January 8, 2025
Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World StudySusana Clemente Bautista, Óscar Segarra Cantón, Núria Padullés-Zamora, et al.
Paediatric Drugs|March 20, 2024
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic ModelSusana Clemente-Bautista, Iñaki F Trocóniz, Óscar Segarra-Cantón, et al.
ERJ Open Research|January 27, 2022
Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countriesOle Hilberg, Anna-Maria Hoffmann-Vold, Vanessa Smith, et al.
Pharmacological Research|July 20, 2023
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in childrenPaula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 24, 2024
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatmentSara Salvador-Martín, Gianluca Rubbini, Perceval Vellosillo, et al.
International Journal of Molecular Sciences|January 21, 2023
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease CohortSara Salvador-Martín, Paula Zapata-Cobo, Marta Velasco, et al.
Pharmaceutics|January 12, 2021
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel DiseaseSara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, et al.
British Journal of Clinical Pharmacology|June 2, 2020
Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel diseaseSara Salvador-Martín, Gemma Pujol-Muncunill, Ferran Bossacoma, et al.
Pageof 4